Literature DB >> 32296769

Distinct Patterns of Internalization of Different Calcitonin Gene-Related Peptide Receptors.

Joseph J Gingell1,2, Tayla A Rees1,2, Erica R Hendrikse1,2, Andrew Siow1,3, David Rennison2,3, John Scotter4, Paul W R Harris1,2,3, Margaret A Brimble1,2,3, Christopher S Walker1,2, Debbie L Hay1,2,5.   

Abstract

Calcitonin gene-related peptide (CGRP) is a neuropeptide that is involved in the transmission of pain. Drugs targeting CGRP or a CGRP receptor are efficacious in the treatment of migraine. The canonical CGRP receptor is a complex of a G protein-coupled receptor, the calcitonin-like receptor (CLR), with an accessory protein, receptor activity-modifying protein 1 (RAMP1). A second receptor, the AMY1 receptor, a complex of the calcitonin receptor with RAMP1, is a dual high-affinity receptor for CGRP and amylin. Receptor regulatory processes, such as internalization, are crucial for controlling peptide and drug responsiveness. Given the importance of CGRP receptor activity in migraine we compared the internalization profiles of both receptors for CGRP using novel fluorescent probes and a combination of live cell imaging, fixed cell imaging, and ELISA. This revealed stark differences in the regulation of each receptor with the AMY1 receptor unexpectedly showing little internalization.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32296769      PMCID: PMC7155191          DOI: 10.1021/acsptsci.9b00089

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  34 in total

1.  RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor.

Authors:  L M McLatchie; N J Fraser; M J Main; A Wise; J Brown; N Thompson; R Solari; M G Lee; S M Foord
Journal:  Nature       Date:  1998-05-28       Impact factor: 49.962

Review 2.  Calcitonin gene-related peptide (CGRP): a new target for migraine.

Authors:  Andrew F Russo
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

3.  Relationship between internalization and calcitonin-induced receptor loss in T 47D cells.

Authors:  D M Findlay; T J Martin
Journal:  Endocrinology       Date:  1984-07       Impact factor: 4.736

Review 4.  New Insights into the Regulation of CGRP-Family Receptors.

Authors:  Joseph J Gingell; Erica R Hendrikse; Debbie L Hay
Journal:  Trends Pharmacol Sci       Date:  2018-12-04       Impact factor: 14.819

5.  Morphine activates opioid receptors without causing their rapid internalization.

Authors:  D E Keith; S R Murray; P A Zaki; P C Chu; D V Lissin; L Kang; C J Evans; M von Zastrow
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

6.  Interaction with beta-arrestin determines the difference in internalization behavor between beta1- and beta2-adrenergic receptors.

Authors:  T Shiina; A Kawasaki; T Nagao; H Kurose
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

7.  Differences in endosomal targeting of human (beta)1- and (beta)2-adrenergic receptors following clathrin-mediated endocytosis.

Authors:  Wei Liang; Patricia K Curran; Quang Hoang; R Travis Moreland; Peter H Fishman
Journal:  J Cell Sci       Date:  2004-01-20       Impact factor: 5.285

8.  Convergent chemoenzymatic synthesis of a library of glycosylated analogues of pramlintide: structure-activity relationships for amylin receptor agonism.

Authors:  Renata Kowalczyk; Margaret A Brimble; Yusuke Tomabechi; Antony J Fairbanks; Madeleine Fletcher; Debbie L Hay
Journal:  Org Biomol Chem       Date:  2014-07-17       Impact factor: 3.876

9.  Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.

Authors:  Joseph J Gingell; Erica R Burns; Debbie L Hay
Journal:  Endocrinology       Date:  2013-12-20       Impact factor: 4.736

10.  Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin.

Authors:  Rebekah L Bower; Lauren Yule; Tayla A Rees; Giuseppe Deganutti; Erica R Hendrikse; Paul W R Harris; Renata Kowalczyk; Zachary Ridgway; Amy G Wong; Katarzyna Swierkula; Daniel P Raleigh; Augen A Pioszak; Margaret A Brimble; Christopher A Reynolds; Christopher S Walker; Debbie L Hay
Journal:  ACS Pharmacol Transl Sci       Date:  2018-04-23
View more
  13 in total

Review 1.  Mediators of Amylin Action in Metabolic Control.

Authors:  Christina N Boyle; Yi Zheng; Thomas A Lutz
Journal:  J Clin Med       Date:  2022-04-15       Impact factor: 4.964

2.  Calcitonin receptor antibody validation and expression in the rodent brain.

Authors:  Erica R Hendrikse; Tayla A Rees; Zoe Tasma; Christelle Le Foll; Thomas A Lutz; Andrew Siow; Peter J Wookey; Christopher S Walker; Debbie L Hay
Journal:  Cephalalgia       Date:  2022-04-11       Impact factor: 6.075

3.  Picomolar Affinity Antagonist and Sustained Signaling Agonist Peptide Ligands for the Adrenomedullin and Calcitonin Gene-Related Peptide Receptors.

Authors:  Jason M Booe; Margaret L Warner; Augen A Pioszak
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-24

4.  Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.

Authors:  Andrew M Strassman; Agustin Melo-Carrillo; Timothy T Houle; Aubrey Adams; Mitchell F Brin; Rami Burstein
Journal:  Cephalalgia       Date:  2022-03-25       Impact factor: 6.075

5.  Migraine therapeutics differentially modulate the CGRP pathway.

Authors:  Minoti Bhakta; Trang Vuong; Tetsuya Taura; David S Wilson; Jennifer R Stratton; Kimberly D Mackenzie
Journal:  Cephalalgia       Date:  2021-02-24       Impact factor: 6.292

Review 6.  Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases.

Authors:  Nina Sonne; Morten A Karsdal; Kim Henriksen
Journal:  Mol Metab       Date:  2020-11-07       Impact factor: 7.422

7.  Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics.

Authors:  T Pooventhiran; Ephraim Felix Marondedze; Penny Poomani Govender; Utsab Bhattacharyya; D Jagadeeswara Rao; Elham S Aazam; Jinesh M Kuthanapillil; Tomlal Jose E; Renjith Thomas
Journal:  J Mol Model       Date:  2021-09-04       Impact factor: 1.810

8.  Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors.

Authors:  Michael L Garelja; Rebekah L Bower; Margaret A Brimble; Shanan Chand; Paul W R Harris; Muhammad Aqfan Jamaluddin; Jakeb Petersen; Andrew Siow; Christopher S Walker; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2021-10-15       Impact factor: 8.739

9.  Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.

Authors:  Francis S Willard; Jonathan D Douros; Maria Bn Gabe; Aaron D Showalter; David B Wainscott; Todd M Suter; Megan E Capozzi; Wijnand Jc van der Velden; Cynthia Stutsman; Guemalli R Cardona; Shweta Urva; Paul J Emmerson; Jens J Holst; David A D'Alessio; Matthew P Coghlan; Mette M Rosenkilde; Jonathan E Campbell; Kyle W Sloop
Journal:  JCI Insight       Date:  2020-09-03

Review 10.  Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.

Authors:  Andrew Blumenfeld; Paul L Durham; Alexander Feoktistov; Debbie L Hay; Andrew F Russo; Ira Turner
Journal:  Neurol Ther       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.